• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (42)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Public Health  • Public Health, Other  • Drug Therapy  • Drug Therapy, Other  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

G. Caleb Alexander, MD, MS; Niraj L. Sehgal, MD, MPH; Rachael M. Moloney, BA; Randall S. Stafford, MD, PhD

Arch Intern Med. 2008;168(19):2088-2094.

Background  Diabetes mellitus is common, costly, and increasingly prevalent. Despite innovations in therapy, little is known about patterns and costs of drug treatment.

Methods  We used the National Disease and Therapeutic Index to analyze medications prescribed between 1994 and 2007 for all US office visits among patients 35 years and older with type 2 diabetes. We used the National Prescription Audit to assess medication costs between 2001 and 2007.

Results  The estimated number of patient visits for treated diabetes increased from 25 million (95% confidence interval [CI], 23 million to 27 million) in 1994 to 36 million (95% CI, 34 million to 38 million) by 2007. The mean number of diabetes medications per treated patient increased from 1.14 (95% CI, 1.06-1.22) in 1994 to 1.63 (1.54-1.72) in 2007. Monotherapy declined from 82% (95% CI, 75%-89%) of visits during which a treatment was used in 1994 to 47% (43%-51%) in 2007. Insulin use decreased from 38% of treatment visits in 1994 to a nadir of 25% in 2000 and then increased to 28% in 2007. Sulfonylurea use decreased from 67% of treatment visits in 1994 to 34% in 2007. By 2007, biguanides (54% of treatment visits) and glitazones (thiazolidinediones) (28%) were leading therapeutic classes. Increasing use of glitazones, newer insulins, sitagliptin phosphate, and exenatide largely accounted for recent increases in the mean cost per prescription ($56 in 2001 to $76 in 2007) and aggregate drug expenditures ($6.7 billion in 2001 to $12.5 billion in 2007).

Conclusions  Increasingly complex and costly diabetes treatments are being applied to an increasing population. The magnitude of these rapid changes raises concerns about whether these more costly therapies will result in proportionately improved outcomes.

Author Affiliations: Department of Medicine, University of Chicago Hospitals (Dr Alexander and Ms Moloney), MacLean Center for Clinical Medical Ethics, University of Chicago (Dr Alexander), and Department of Pharmacy Practice, University of Illinois at Chicago School of Pharmacy (Dr Alexander), Chicago, Illinois; Division of Hospital Medicine, University of California, San Francisco (Dr Sehgal); and Program on Prevention Outcomes and Practices, Stanford Prevention Research Center, and Stanford University School of Medicine, Stanford, California (Dr Stafford).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

In This Issue of Archives of Internal Medicine
Arch Intern Med. 2008;168(19):2063.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians
Qaseem et al.
ANN INTERN MED 2012;156:218-231.
ABSTRACT | FULL TEXT  

Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells
Salani et al.
FASEB J. 2012;26:788-798.
ABSTRACT | FULL TEXT  

Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control
Hirst et al.
Diabetes Care 2012;35:446-454.
ABSTRACT | FULL TEXT  

Evaluation of Guideline Recommendations on Oral Medications for Type 2 Diabetes Mellitus: A Systematic Review
Bennett et al.
ANN INTERN MED 2012;156:27-36.
ABSTRACT | FULL TEXT  

Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
Bennett et al.
ANN INTERN MED 2011;154:602-613.
ABSTRACT | FULL TEXT  

Switching From Rosiglitazone: Thinking Outside the Class
Lipska and Ross
JAMA 2011;305:820-821.
FULL TEXT  

Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes
Azoulay et al.
Cancer Epidemiol. Biomarkers Prev. 2011;20:337-344.
ABSTRACT | FULL TEXT  

Time for Clinically Relevant Comparative Effectiveness Studies in Type 2 Diabetes
Nathan
ANN INTERN MED 2011;154:131-132.
FULL TEXT  

More Reasons to Say Goodbye to Glyburide
Riddle
J. Clin. Endocrinol. Metab. 2010;95:4867-4870.
FULL TEXT  

Trends in Diabetes Medication Use and Prevalence of Geriatric Syndromes in Older Mexican Americans from 1993/1994 to 2004/2005
Beard et al.
The Annals of Pharmacotherapy 2010;44:1376-1383.
ABSTRACT | FULL TEXT  

Changes in Glitazone Use Among Office-Based Physicians in the U.S., 2003-2009
Cohen et al.
Diabetes Care 2010;33:823-825.
ABSTRACT | FULL TEXT  

Individualizing Care for the Many: The Evolving Role of Professional Continuous Glucose Monitoring Systems in Clinical Practice
Nardacci et al.
The Diabetes Educator 2010;36:4S-19S.
ABSTRACT | FULL TEXT  

Income-related differences in mortality among people with diabetes mellitus
Lipscombe et al.
CMAJ 2010;182:E1-E17.
ABSTRACT | FULL TEXT  

Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus
BLONDE
Cleveland Clinic Journal of Medicine 2009;76:S4-S11.
ABSTRACT | FULL TEXT  

Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk
PETERS
Cleveland Clinic Journal of Medicine 2009;76:S20-S27.
ABSTRACT | FULL TEXT  

Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
DAVIDSON
Cleveland Clinic Journal of Medicine 2009;76:S28-S38.
ABSTRACT | FULL TEXT  

Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects
CEFALU et al.
Cleveland Clinic Journal of Medicine 2009;76:S39-S47.
ABSTRACT | FULL TEXT  

Trends in Medication Use Among US Adults With Diabetes Mellitus: Glycemic Control at the Expense of Controlling Cardiovascular Risk Factors
Mann et al.
Arch Intern Med 2009;169:1718-1720.
FULL TEXT  

The Net Value of Health Care for Patients With Type 2 Diabetes, 1997 to 2005
Eggleston et al.
ANN INTERN MED 2009;151:386-393.
ABSTRACT | FULL TEXT  

Secular Trends in Diabetes-Related Preventable Hospitalizations in the United States, 1998-2006
Wang et al.
Diabetes Care 2009;32:1213-1217.
ABSTRACT | FULL TEXT  

Improving Diabetes Care: The Model for Health Care Reform
Kahn and Anderson
Diabetes Care 2009;32:1115-1118.
FULL TEXT  

Insulin Pump Therapy: Guidelines for Successful Outcomes
Scheiner et al.
The Diabetes Educator 2009;35:29S-41S.
ABSTRACT | FULL TEXT